Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine
ACS Medicinal Chemistry Letters August 21, 2024 DOI: 10.1021/acsmedchemlett.4c00414 via OpenAlex
Summary
AI-generated from the abstractRecent psychedelic research has produced lysergic acid derivatives with modified LSD-like effects, a psilocybin dosing method guided by ABCF1 gene expression, and new treatments for binge eating disorder. Neuroenhancement techniques that boost emotional responses are also being explored. These developments point toward personalized medicine and expanded mental health applications, signaling a transformative phase in clinical psychedelic use.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Psilocybin |
| Keywords | Transformative learning Hallucinogen Psychology |
| Key finding | Novel lysergic acid derivatives, ABCF1-based psilocybin dosing, and psychedelic treatments for binge eating disorder represent emerging advances in personalized psychedelic medicine. |
Abstract
This article explores groundbreaking advancements in psychedelic research, highlighting the development of novel lysergic acid derivatives with modified LSD-like actions and innovative dosing methods based on ABCF1 gene expression for psilocybin. It also examines new strategies for treating binge eating disorder using psychedelics and techniques for neuroenhancement to enhance emotional responses. These developments offer fresh insights into the therapeutic potential of psychedelics, underscoring their significance in personalized medicine and mental health treatment. The article delves into the implications of these novel approaches, signaling a transformative phase in the application of psychedelics in clinical settings.